Portfolio news 0

C-Capture Ltd

C-Capture’s technology in biofuels trial to achieve net zero

Microbiotica Ltd

Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients

Storm Therapeutics

STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024

Oxford Nanopore Technologies Plc

Oxford Nanopore announces senior leadership changes

Genomics

New study from Genomics indicates individuals who have a genetic predisposition for high BMI may require tailored approaches to tackle obesity

Oxford Nanopore Technologies Plc

New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore

Ieso Digital Health

ieso Digital Health Appoints Kent Tangen as New CEO to Drive Digital Mental Health Innovation in the United States

Diffblue Ltd

Diffblue Secures $6.3 Million in New Funding Amidst 3x Growth Period

Oxa

Oxa Unveils Autonomous Ford E-Transit Van and Minibus

Kynos Therapeutics Ltd

Dr. Falk Pharma acquires Kynos Therapeutics, adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio